Clinical Trial Update: A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase II open-label, multi-arm trial in Chinese patients with advanced non-small cell lung cancer tested AUY922, BYL719, INC280, LDK378, and MEK162; study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AUY922 (luminespib)
• BYL719 (alpelisib)
• INC280
• LDK378 (Alectinib)
• MEK162 (binimetinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-12-16